Colorectal Cancer (CRC) Completed Phase 1 Trials for Paclitaxel (DB01229)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04068896	Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy	Treatment	Gemcitabine (DB00441) NGM120 (DB22317) Paclitaxel (DB01229)
NCT03798626	Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers	Treatment	Bevacizumab (DB00112) Cabozantinib (DB08875) Fluorouracil (DB00544) Gevokizumab (DB12119) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Ramucirumab (DB05578)
NCT03329950	A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	Treatment	CDX-1140 (DB22517) CDX-301 (DB19293) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT00667641	Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors	Treatment	Bortezomib (DB00188) Paclitaxel (DB01229)
NCT03314935	A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors	Treatment	Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Leucovorin (DB00650) Numidargistat (DB15286) Oxaliplatin (DB00526) Paclitaxel (DB01229)
NCT02574663	TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors	Treatment	Bevacizumab (DB00112) Fluorouracil (DB00544) Gemcitabine (DB00441) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Umbralisib (DB14989)
NCT01803282	Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors	Treatment	Andecaliximab (DB12296) Bevacizumab (DB00112) Carboplatin (DB00958) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pemetrexed (DB00642)
NCT00107250	AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)	Treatment	Capecitabine (DB01101) Carboplatin (DB00958) Cediranib (DB04849) Paclitaxel (DB01229)